Texas Equine Veterinary Association

2019 Fall Edition - The Remuda

Texas Equine Veterinary Association Publications

Issue link: http://aspenedgemarketing.uberflip.com/i/1174368

Contents of this Issue

Navigation

Page 28 of 31

www.texasequineva.com • 29 BRIEF SUMMARY: Prior to use please consult the product insert, a summary of which follows: CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATIONS: Adequan ® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. CONTRAINDICATIONS: There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. WARNINGS: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. PRECAUTIONS: The safe use of Adequan ® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated. For customer care, or to obtain product information, visit www.adequan.com. To report an adverse event please contact American Regent, Inc. at (800) 734-9236 or email pv@americanregent.com. Please see Full Prescribing Information at www.adequan.com. Over the past 30 years, Adequan ® i.m. (polysulfated glycosaminoglycan) has been recommended millions of times 1 to treat degenerative disease, and with good reason. From day one, it's been the only FDA-Approved equine PSGAG joint precription available, and the only one proven to. 2, 3 Restore synovial joint lubrication Repair joint cartilage Reverse the disease cycle Reduce infl ammation When you start with it early and stay with it as needed, horses may enjoy greater mobility over a lifetime. 2, 4, 5 Discover if Adequan is the right choice. Talk to your American Regent Animal Health sales representative or call (800) 458-0163 to order. There's nothing else like it. 1 Data on fi le. 2 Adequan ® i.m. Package Insert, Rev 1/19. 3 Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fl uid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703. 4 Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57. 5 McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse.St. Louis, MO: Elsevier, 2016; 33-48. Adequan and the Horse Head design are registered trademarks of American Regent, Inc. © 2019, American Regent, Inc. PP-AI-US-0222 2/2019

Articles in this issue

Links on this page

view archives of Texas Equine Veterinary Association - 2019 Fall Edition - The Remuda